Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 224 | 282 | 281 | 320 | 339 | 392 | 459 | 498 |
| Operating profit | €m | 7 | 32 | ||||||
| Net profit | €m | 31 | 47 | 8 | -51 | -20 | -21 | 14 | 27 |
| EPS reported | € | -0.64 | 0.43 | ||||||
| Operating cashflow per share | € | 2.36 | 1.59 | ||||||
| Capex per share | € | 3.29 | 3.10 | ||||||
| FCF per share | € | -0.92 | -1.51 | ||||||
| Free cash flow | €m | -30 | -50 | ||||||
| Net debt | €m | 35 | 80 | ||||||
| Book value equity | €m | 340 | 352 | ||||||
| Book value per share | € | 10.31 | 10.67 | ||||||
| Number of shares | m | 32.99 | 33.02 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.72 | 4.43 | ||||||
| P/S LTM | x | 2.36 | 3.40 | ||||||
| P/FCF LTM | x | -30.38 | -31.36 | ||||||
| EV/EBITDA LTM | x | 22.08 | 20.76 | ||||||
| EV/Sales LTM | x | 2.50 | 3.58 | ||||||
| Earnings Yield LTM | % | -2.30% | 0.92% | ||||||
| FCF Yield | % | -3.29% | -3.19% | ||||||
| Quality | |||||||||
| ROE | % | -6.26% | 4.17% | ||||||
| ROIC | % | 1.14% | 2.72% | ||||||
| Operating margin | % | 1.89% | 6.98% | ||||||
| Gross margin | % | 16.41% | 22.58% | ||||||
| FCF/Sales | % | -7.77% | -10.84% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +15.70% | +24.40% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.23 | -0.36 | ||||||
| Net Debt/EBITDA | x | 1.26 | 1.02 | ||||||
| EBIT/Net interest | x | 0.40 | 1.33 | ||||||
| Net debt/market cap | % | 3.78% | 5.15% | ||||||
| Net debt/Equity | x | 0.10 | 0.23 | ||||||
| Gross debt/equity | x | 0.38 | 0.40 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free